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Glial cells have a variety of functions in the brain, ranging from immune defense against
external and endogenous hazardous stimuli, regulation of synaptic formation, calcium
homeostasis, and metabolic support for neurons. Their dysregulation can contribute
to the development of neurodegenerative disorders, including Alzheimer’s disease (AD).
One of the most important functions of glial cells in AD is the regulation of Amyloid-β (Aβ)
levels in the brain. Microglia and astrocytes have been reported to play a central role
as moderators of Aβ clearance and degradation. The mechanisms of Aβ degradation
by glial cells include the production of proteases, including neprilysin, the insulin
degrading enzyme, and the endothelin-converting enzymes, able to hydrolyse Aβ at
different cleavage sites. Besides these enzymes, other proteases have been described
to have some role in Aβ elimination, such as plasminogen activators, angiotensin-
converting enzyme, and matrix metalloproteinases. Other relevant mediators that are
released by glial cells are extracellular chaperones, involved in the clearance of Aβ
alone or in association with receptors/transporters that facilitate their exit to the blood
circulation. These include apolipoproteins, α2macroglobulin, and α1-antichymotrypsin.
Finally, astrocytes and microglia have an essential role in phagocytosing Aβ, in many
cases via a number of receptors that are expressed on their surface. In this review, we
examine all of these mechanisms, providing an update on the latest research in this field.
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INTRODUCTION
The pathogenesis of Alzheimer’s disease (AD) has been associated with the presence of extracellular
amyloid-β peptide (Aβ) aggregates, forming neuritic plaques, as well as intra-neuronal Aβ (Gouras
et al., 2005; Blair et al., 2014), probably due to alterations in the mechanisms of generation and/or
clearance of amyloid in the brain during aging. There is evidence of an increase in the expression
of β-APP cleaving enzyme-1 (BACE1), the enzyme responsible for the cleavage of the amyloid
precursor protein (APP) in the amyloidogenic pathway, in sporadic AD cases (Holsinger et al.,
2002; Yang et al., 2003). In addition, the dysregulation of the systems involved in the clearance and
degradation of Aβ has generated a lot of interest in the last decade, particularly their effect on the
accumulation of Aβ in the blood vessel walls, leading to cerebral amyloid angiopathy (Love, 2004).
A great number of reviews have examined the main mechanisms of Aβ clearance and
degradation (Bates et al., 2009; Saido and Leissring, 2012; Yoon and Jo, 2012; Tarasoff-Conway
et al., 2015). These include Aβ proteases, which are enzymes that degrade or cleave Aβ into
smaller fragments. Other proteins with a crucial role in Aβ clearance are apolipoprotein E (ApoE)
and α2-macroglobulin (α2-M); they interact with transporters including low-density lipoprotein
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receptor-related protein 1 (LRP1) receptors, very low-density
lipoprotein receptor (VLDLR), and P-glycoprotein, localized in
astrocytes and on the abluminal side of the cerebral endothelium,
where they facilitate the transport of Aβ across the blood brain
barrier (BBB) into the blood circulation (Deane et al., 2009).
Genetic mutations resulting in loss of function of those proteins
have demonstrated their importance in disease progression,
particularly in late onset AD, although there are indications
of alterations of some of the Aβ proteases by environmental
factors (Table 1). Experimental data have suggested that Aβ and
solutes can normally also be cleared along the lymphatic drainage
pathways within the basement membranes of capillaries and
arteries (Carare et al., 2008; Tarasoff-Conway et al., 2015). Lastly,
another way to eliminate Aβ from the brain is by the uptake
and phagocytosis of Aβ by cells such as microglia, astrocytes, and
macrophages.
Many of the mechanisms mentioned above are mediated by
glial cells. Here, we review how glial cells are mediators of Aβ
removal from the brain (schematic Figure 1).
Aβ DEGRADING PROTEASES
Many of the proteins involved in the enzymatic degradation of Aβ
are produced by glial cells. These proteases cleave at different sites
within the Aβ sequence, resulting in different enzymatic products
(Nalivaeva et al., 2012). These include:
Metalloendopeptidases
Neprilysin (NEP), the insulin degrading enzyme (IDE) and
endothelin-converting enzymes-1 and -2 (ECE1 and ECE2)
(Eckman et al., 2001, 2003) are metalloendopeptidases
particularly involved in the degradation of monomeric Aβ
species (although neprilysin can also hydrolyse oligomeric
forms). ECEs are expressed in neurons, endothelial cells (Naidoo
et al., 2004), and astrocytes (Nakagomi et al., 2000) and primarily
degrade Aβ intracellularly (Eckman et al., 2003). NEP is mainly
expressed in pre-synaptic terminals of neurons (Fukami et al.,
2002) but can also be found in activated astrocytes (Fisk et al.,
2007; Yamamoto et al., 2014) and microglia (Hickman et al.,
2008). In the brain, IDE is synthesized and secreted by neurons,
oligodendrocytes, and microglia (Bernstein et al., 2008), where
it is released via exosomes (Tamboli et al., 2010) especially
acting on extracellular Aβ deposits. IDE is unequally expressed
in human brain, majorly found in hypothalamic neurons and
in hippocampus, cerebellum, and brain stem (Bernstein et al.,
2008), coinciding with the location of insulin receptors in the
brain.
The relevance of NEP and IDE has been proven in knockout
models, whereby mice lacking those enzymes crossed with APP
transgenic models show increased Aβ deposition (Iwata et al.,
2001; Farris et al., 2003) in the brain. Conversely, overexpression
of these proteases has been shown to reduce Aβ load (Leissring
et al., 2003).
The expression of NEP and IDE in glial cells has been found
to change depending on the stage of the disease. In vitro and
in vivo studies have shown that IDE and ECE are up-regulated
in response to increasing levels of brain Aβ (Zhao et al., 2007),
while NEP has been found reduced in AD brains (Wang et al.,
2010).
Plasminogen Activators and ACE
Other enzymes also involved in Aβ degradation, but whose
relevance depends on the degree of Aβ pathology, are
plasminogen activators and angiotensin-converting enzyme
(ACE) (Hu et al., 2001), which are more effective for
aggregated Aβ rather than regulating steady-state Aβ levels
(Saido and Leissring, 2012). While ACE is mainly neuronal,
tissue plasminogen activator (tPA) is synthesized by neurons and
microglial cells (Melchor and Strickland, 2005).
Matrix Metalloproteinases (MMPs)
Matrix metalloproteinases, known to be expressed and secreted
by astrocytes, play a role in the extracellular degradation of both
monomeric and fibrillar forms of Aβ (Yan et al., 2006). Astrocytes
surrounding amyloid plaques show enhanced expression of
MMP-2 and MMP-9 in aged APP/presenilin 1 mice. Moreover,
astrocyte-conditioned medium (ACM) degraded Aβ, lowering
its levels and producing several fragments after incubation with
synthetic human Aβ(1–40) and Aβ(1–42). This activity was
attenuated with specific inhibitors of MMP-2 and -9, as well as in
ACM derived from mmp-2 or -9 knockout (KO) mice (Yin et al.,
2006).
Lysosomal Peptidases
It has been described that after being phagocytosed by microglia,
Aβ can be degraded by cathepsin B (CAT-B) (Nakanishi, 2003;
Halle et al., 2008). This enzyme is able to reduce longer forms of
Aβ into shorter less toxic species, such as Aβ38. In addition, ECE-
2 can be found expressed in endosomes/lysosomes where it can
mediate the degradation of Aβ (Pacheco-Quinto and Eckman,
2013).
PROTEASOMAL DEGRADATION
The ubiquitin proteasome system (UPS) is a mechanism of
protein degradation which selectively targets individual proteins,
including short-lived, damaged, or defectively folded proteins
(Rock et al., 1994; Lilienbaum, 2013). Before a protein is degraded
by the proteasome, the ubiquitin (Ub) system selects the protein
target by the conjugation of Ub carried out by the serial activity
of several enzymes (E1–E3) along the pathway. It has been
shown that the proteasomal degradation machinery is capable
of cleaving Aβ(1–42) peptides in a dose-dependent manner,
without significantly affecting the overall catalytic function of the
proteasome (Zhao and Yang, 2010). In addition, it was shown
that E2 conjugating enzymes, E3 ligases, and de-ubiquitinating
enzymes play a pivotal role in the proteasomal degradation of Aβ
(Hong et al., 2014). Interestingly, it seems that the UPS system
in glial cells is more efficient at degrading aggregated proteins
compared with neurons (Jansen et al., 2014), and this could
explain why they do not contain protein aggregates. However, in
Frontiers in Aging Neuroscience | www.frontiersin.org 2 July 2016 | Volume 8 | Article 160
fnagi-08-00160 July 1, 2016 Time: 14:38 # 3
Ries and Sastre Aβ Degradation by Glia
TABLE 1 | Genetic vs environmental factors affecting Aβ clearance.
Genetic factors Environmental factors
ApoE mutations (Verghese et al., 2013) Metal ions affect expression of IDE, NEP and metalloproteases (Sastre et al., 2015)
ApoJ mutations (Harold et al., 2009) Insulin/diabetes affects IDE levels (Steneberg et al., 2013)
Presenilin mutations affect microglia function (Farfara et al., 2011) Oxidative stress regulates IDE (Stocker and Keaney, 2004)
TREM-2 mutations (Kleinberger et al., 2014)
FIGURE 1 | Mechanisms of Aβ clearance by glial cells. Astrocytes and microglia can produce Aβ degrading proteases neprilysin (NEP), endothelin-converting
enzyme (ECE), insulin degrading enzyme (IDE), matrix metalloproteases (MMPs), cathepsin B (CAT-B) as well as chaperones apolipoprotein E (ApoE), apolipoprotein
J (ApoJ), α-2 macroglobulin (α2-M), α1-antichymotrypsin (ACT) involved in the clearance of Aβ. Receptors located in the surface of glial cells such as lipoprotein
receptor-related protein 1 (LRP-1), scavenger receptors (SR), formyl peptide receptors (FPR), macrophage receptor with collagenous structure (MARCO), receptor
for advanced glycation end products (RAGE) and triggering receptor expressed on myeloid cells 2 (TREM-2) are involved in the uptake and clearance of Aβ (receptor
mediated endocytosis). Astrocytes are also connected to blood vessels, where they are implicated in the draining of Aβ and other products out of the brain.
neurodegenerative diseases the UPS system in glia could become
dysfunctional and contribute to the progression of the disease.
AUTOPHAGIC DEGRADATION
The autophagy pathway is critical for the turnover of cell
organelles and degradation of aggregated proteins in cells
under stress. It was hypothesized that a defective clearance of
Aβ-generating autophagic vacuoles creates conditions favorable
for Aβ accumulation in AD and this is supported by data
indicating that increasing autophagy by rapamycin reduces
amyloid burden in vivo (Nixon, 2007). The role of autophagy
in the degradation of Aβ has not been investigated in glial cells
until recently. Cho and colleagues reported the importance of
autophagy in the clearance of extracellular Aβ fibrils by microglia
and in the regulation of the Aβ-induced NLRP3 (NLR Family,
Pyrin Domain Containing 3) inflammasome using microglia
from atg7 knockout mice and in vitro cultures (Cho et al., 2014).
Interestingly, microglia isolated from human AD brains show
significantly reduced beclin 1 and retromer protein levels (Lucin
et al., 2013). In addition, astrocytes from transgenic AD models
showed strong expression of microtubule-associated protein light
chain 3 (LC3), and autophagy seems to be involved in Aβ
internalization by those cells (Pomilio et al., 2016), providing a
link between autophagy and phagocytosis.
Aβ CLEARANCE BY EXTRACELLULAR
CHAPERONES
These include proteins that bind Aβ in plasma and cerebrospinal
fluid (CSF), such as albumin, α2M, α1-antichymotrypsin (ACT),
serum amyloid P component (SAP), complement proteins,
transthyretin, apoferritin, apolipoproteins, and lipoproteins
(Bates et al., 2009), which are essential because they modulate the
formation of Aβ fibrils and mediate the interaction of Aβ with
LRP-1 receptors in astrocytes.
Apolipoprotein E (ApoE)
It is the major risk factor for late onset AD. It is produced
primarily by astrocytes in the brain and has been implicated in the
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degradation of Aβ in these cells (Koistinaho et al., 2004), although
it can be produced by microglia and neurons in response to
stimuli from glial cells (Saura et al., 2003; Harris et al., 2004).
It has been shown that ApoE binds Aβ, and this association
is more efficient with the ApoE2 and E3 isoforms than with
ApoE4; these complexes are thought to influence both seeding
of fibrillar Aβ and transport of soluble Aβ (Wildsmith et al.,
2013). However, some recent controversial reports indicate that
ApoE does not bind Aβ but competes with Aβ for binding
to LRP-1 in astrocytes, and this could impact Aβ clearance
by glia and across the blood–brain barrier (BBB) (Verghese
et al., 2013). However, it is clear that ApoE has a role on Aβ
clearance because bexarotene, which enhances ApoE expression,
clears Aβ and improves cognition in mice (Cramer et al.,
2012).
Apolipoprotein J (ApoJ or Clusterin)
Apolipoprotein J has been shown to interact with Aβ and alters
its ability to form fibrils as well as modifying Aβ-mediated
neurotoxicity. Similarly to ApoE, ApoJ is also produced
in astrocytes. ApoJ is known to facilitate the transport of
Aβ and hence the clearance across the BBB through the
megalin/LRP-2 receptor. Upon exposure to Aβ combined
with ApoE, ApoJ, ACT and a combination of SAP and
complement C1q, a clear reduction in astrocytic but not
microglial oligomeric Aβ uptake was observed (Mulder et al.,
2014).
α1-Antichymotrypsin (ACT)
α1-Antichymotrypsin is a serine protease inhibitor that has
been reported to bind Aβ and is overexpressed in the brain
of AD patients (Abraham, 2001). ACT has been shown to be
produced in astrocytes (Abraham et al., 1989) and its expression
is regulated by proinflammatory cytokines including interleukin
(IL)-1, oncostatin M (OSM), and complexes of IL-6, soluble IL-
6 receptors and transcriptional regulators such as nuclear factor
1-X and activator protein 1 (AP-1; Gopalan et al., 2006a,b).
α2-Macroglobulin (α2-M)
α2-Macroglobulin is a matrix metalloproteinase inhibitor
that is also released by glial cells, in particular perivascular
astrocytes (Cucullo et al., 2003). Microinjection of clusterin
and α2-M into the hippocampus of rat brains were
found to prevent Aβ42-induced learning and memory
impairments and reduce Aβ42-induced glial inflammation
and neuronal degeneration (Cascella et al., 2013), suppressing
oligomer cytotoxicity. α2-M can act as a ligand for LRP-1
(Kanekiyo et al., 2014), promoting increased neurite
outgrowth in primary sensory neurons (Yamauchi et al.,
2013).
Aβ INTERNALISATION
An important mechanism of Aβ clearance from the brain is
its uptake by glial cells. Aβ can be internalized by microglia,
astrocytes, and other immune cells such as macrophages.
Pinocytosis
Soluble Aβ can be cleared by microglia through fluid phase
pinocytosis (Mandrekar et al., 2009), with spontaneous formation
and internalization of pinosomes from membrane ruﬄes.
Furthermore, soluble Aβ(1–42) is able to induce its pinocytic self-
uptake by stimulating the P2Y4 receptor and the PI3kinase/Akt
cascade through autocrine ATP signaling on microglia (Li et al.,
2013).
Phagocytosis
It is widely accepted that microglia phagocytose fibrillar
Aβ, particularly more vigorously when bound by the C3b
complement system (Lee and Landreth, 2010). Interestingly,
the induction of microglial phagocytosis by fibrillar Aβ is
attenuated by oligomeric Aβ (Pan et al., 2011). Astrocytes can
also endocytose monomeric and oligomeric Aβ through actin
regulation (Lee et al., 2015). In addition, there is evidence that
astrocytes are able to phagocytose neurons containing Aβ (Nagele
et al., 2003).
Receptor-Mediated Endocytosis
Oligomeric and fibrillar Aβ are primarily internalized though
receptor-mediated endocytosis, via a number of receptors that are
expressed on the surface of microglia and astrocytes:
Scavenger Receptors (SR)
Scavenger receptor type-A (SR-A), type B1 (SR-B1), CD36
and CD40 are able to bind and mediate the endocytosis of
oligomeric and fibrillar Aβ (Paresce et al., 1996; Coraci et al.,
2002; Husemann et al., 2002; El Khoury et al., 2003; Yang
et al., 2011). SR-As can act in conjunction with other receptors,
such as complement receptor 3 (also known as Mac-1/CD11b)
to promote the uptake of fibrillar Aβ in microglia (Fu et al.,
2012). On the other hand, the class B scavenger receptors
CD36/SR-BII are not involved in oligomeric Aβ clearance, but
can affect the recruitment and activation of microglia in response
to fibrillar Aβ (Coraci et al., 2002; El Khoury et al., 2003).
Fibrillar Aβ also acts as a scaffold for the assembly of a receptor
complex consisting of CD36, alpha6beta1-integrin, and CD47
(Bamberger et al., 2003). Besides microglia, some types of SRs
are expressed by astrocytes, including SR-BI and SR-MARCO
(macrophage receptor with collagenous structure; Alarcon et al.,
2005).
Toll-Like Receptors (TLR)
Toll-like receptors are involved in the microglial clearance of
monomeric, oligomeric, and fibrillar Aβ (Tahara et al., 2006;
Reed-Geaghan et al., 2009). TLR2 and TLR4 are directly involved
in the microglial phagocytic response to Aβ, or indirectly with
other receptors, as in the case of TLR9 activation by Aβ through
the upregulation of formyl peptide receptor-2 (FPR2; Iribarren
et al., 2005). The phagocytosis of fibrillar Aβ(1–42) by microglia
can also be mediated through the LPS receptor CD14, a co-
receptor of the functional TLR complex (Liu et al., 2005). Studies
performed in TLR2 and TLR4 knockout mice have confirmed
the importance of these receptors in Aβ clearance, showing
increased Aβ deposition (Tahara et al., 2006; Richard et al., 2008;
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Birch et al., 2014). Some TLRs are also expressed in astrocytes
and respond to TLR activators by secreting pro-inflammatory
molecules (Gorina et al., 2009; van Noort and Bsibsi, 2009;
Trudler et al., 2010).
Receptor for Advanced Glycation End Products
(RAGE)
Although RAGE receptors have been mainly involved in
mediating the inflammatory cascade in activated microglia
(Solito and Sastre, 2012), their role in Aβ phagocytosis in
astrocytes has been recently demonstrated when blocking these
receptors with specific antibodies (Jones et al., 2013).
Formyl Peptide Receptors (FPR)
Formyl peptide receptors are a group of seven-transmembrane
G protein coupled receptors (Le et al., 2002) and are expressed
in neurons, microglia and astrocytes (Panaro et al., 2007; Braun
et al., 2011). There is evidence that the FPRL1/FPR2 subtype
binds to Aβ(1–42) and activates microglial internalization of the
Aβ/FPRL1 complex in a PLD dependent-manner in microglia
(Le et al., 2001; Brandenburg et al., 2008) and astrocytes
(Brandenburg et al., 2008). In addition, both RAGE and SR-
MARCO are known to form complexes with FPRL1/FPR2 in
the presence of Aβ, initiating microglial signaling cascades in
response to Aβ (Brandenburg et al., 2010; Slowik et al., 2012).
Fc Receptors (FcRs)
Fc receptors are expressed in microglia, astrocytes,
oligodendrocytes, and neurons (Okun et al., 2010). Peress
and colleagues first reported FcγRI, FcγRII, and FcγRIII
immunoreactivity in senile plaques and on ramified microglia
throughout the cortex and white matter of healthy controls and
AD patients (Peress et al., 1993). The FcRs have been shown
to mediate Aβ clearance in the presence of anti-Aβ antibodies
(Bard et al., 2000; Wilcock et al., 2003), as observed in Aβ
immunization therapies (Bacskai et al., 2002). The degree of
involvement of Fc receptors in the clearance of Aβ bound
by endogenous antibodies such as IgGs is currently not well
elucidated (Doens and Fernández, 2014).
Triggering Receptor Expressed on Myeloid Cells 2
(TREM2)
Genetic variants of TREM2 receptors were recently identified
as causing increased susceptibility to late onset AD. TREM2
can activate phagocytosis in microglia and reduce TLR-mediated
signaling in macrophages (Klesney-Tait et al., 2006). Missense
mutations associated with FTD and FTD-like syndrome have
been shown to reduce TREM2 maturation and impair the
phagocytic activity of TREM2-expressing cells (Kleinberger et al.,
2014). More recently, it has been demonstrated that TREM2
is able to specifically sense fibrillar Aβ, activating microglial
clustering around plaques, thereby limiting Aβ diffusion and
subsequent toxicity (Wang et al., 2015, 2016).
Lipoprotein Receptor-Related Proteins (LRPs)
Lipoprotein receptor-related protein 1 (LRP1) is a large endocytic
receptor for more than 40 ligands, including ApoE, α2-M and
Aβ, and it is expressed by neurons, vascular cells and glial cells
in the brain. Astrocytes take up Aβ through LRP1 either directly
or indirectly in the presence of amyloid-associated protein ApoE,
with perivascular astrocytes in AD brains found to contain both
Aβ and ApoE (Utter et al., 2008; Kanekiyo et al., 2014). ApoE
deficient astrocytes do not respond as well as wild type astrocytes
to amyloid deposits, suggesting that ApoE is needed for astrocyte
clearance of Aβ (Koistinaho et al., 2004). However, as indicated
above, a recent paper has suggested that in fact ApoE may
compete for the binding of Aβ to LRP-1. LRP-1 can also mediate
Aβ phagocytosis in microglia, confirmed in vitro using LRP1
deficient cells (N’Songo et al., 2013). Furthermore, Aβ can be
taken up when bound to LRP2 together with ApoJ and the
megalin receptor (Zlokovic et al., 1996).
LGI3
The transmembrane protein leucine-rich glioma inactivated
protein 3 co-localizes with Aβ at the astrocytic cell membrane
(Kimura et al., 2007), and its downregulation reduces Aβ
internalization by astrocytes (Okabayashi and Kimura, 2008).
ASTROCYTES AND THE “GLYMPHATIC”
SYSTEM
It has been recently shown that astrocytes may contribute
to the clearance of debris from the brain thanks to their
projections around blood vessels, creating a sort of network
that drains Aβ and other products out of the brain. In vessels,
astrocyte end feet appear to connect to the smooth muscle
layer (Morris et al., 2014). High expression of the channel
aquaporin 4 (AQP-4) at the astrocyte end feet is thought to
help solute clearance due to its role in water transport (Igarashi
et al., 2014). In fact, AQP-4 knock-out mice show hindered
solute clearance including that of Aβ (Iliff and Nedergaard,
2013).
CONCLUSION
Glial cells represent around 50% of the cells in the human
brain (Azevedo et al., 2009). It is well established that in AD
there is an up-regulation in the number and/or activation of
microglia and astrocytes, associated with the deposition of Aβ.
Although many studies have supported the notion that the
activation of these glial cells may have detrimental effects due
to the release of pro-inflammatory mediators such as certain
cytokines and reactive oxygen species, there is evidence that
supports their “protective” role by promoting the removal of Aβ.
This function seems to be associated with a special and particular
phenotype in microglia (formally known as M2 or alternatively
activated) in contrast with the pro-inflammatory M1 state (Tang
and Le, 2016). Therefore, many of the proteins that have been
described in this review may not be expressed throughout life
by glial cells, but their presence may depend on the activation
status of those cells. This may also change during aging, when
there is a dysregulation of glial function and these systems may
become defective, contributing to the accumulation of Aβ in the
brain.
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A number of the studies reported here have outlined the
difficulties of dissecting out each of these specific mechanisms
of Aβ clearance only by using animal models with a specific
deletion for one of those proteins, because many mechanisms
of clearance are interconnected. Besides, some of these proteins
have additional roles in the brain that are not directly related to
the clearance of Aβ and may interfere with the interpretation of
the results.
The therapeutic approaches targeting these clearance
mechanisms have provided promising results, including the
design of vectors carrying genes for NEP, for instance, or
the discovery of drugs that enhance the synthesis of ApoE,
showing reductions in Aβ deposition and improving cognitive
impairments. Therefore, research in this field holds great
potential for the development of new treatments to cure/stop
the progression of AD.
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